

|                          |   |                         |
|--------------------------|---|-------------------------|
| IN THE MATTER OF         | * | BEFORE THE MARYLAND     |
| TIFFANIE E. WHEELER      | * | STATE BOARD OF PHARMACY |
| PHARMACY TECHNICIAN      | * |                         |
| RESPONDENT               | * | CASE NO: 26-030         |
| REGISTRATION NO.: T13151 | * |                         |

\* \* \* \* \*

### **ORDER FOR SUMMARY SUSPENSION**

The Maryland State Board of Pharmacy (the “Board”) hereby **SUMMARILY SUSPENDS** the registration of **Tiffanie E. Wheeler** (the “Respondent”), Registration Number: **T13151**, to practice as a pharmacy technician in the State of Maryland under the Maryland Pharmacy Act (the “Act”), Md. Code Ann., Health Occ. (“Health. Occ.”) §§ 12-101 *et seq.* (2021 Repl. Vol. & 2024 Supp.).

The Board takes such action pursuant to its authority under Md. Code Ann., State Gov’t § 10-226(c) (2021 Repl. Vol. & 2024 Supp.) and Code of Maryland Regulations (“COMAR”) 10.34.01.12F, concluding that the public health, safety, or welfare imperatively requires emergency action.

### **INVESTIGATIVE FINDINGS**

Based on information received by, and made known to the Board, and the investigatory information obtained by, received by, and made known to and available to

the Board, including the instances described below, the Board has reason to believe that the following facts are true:<sup>1</sup>

1. The Respondent was originally issued a registration to practice as a pharmacy technician in Maryland on or about August 6, 2013. The Respondent's registration expires on or about September 31, 2026.

2. At all times relevant hereto, the Respondent was employed at an outpatient retail pharmacy, (the "Pharmacy")<sup>2</sup> located in Baltimore, Maryland. The Respondent began working at the Pharmacy on or about April 28, 2025. The Respondent was terminated by Pharmacy staff on or about August 7, 2025.

3. On or about August 6, 2025, during a monthly routine audit of controlled substances, Pharmacy staff discovered that 414 tablets of Clonazepam 2mg were missing from the pharmacy inventory.<sup>3</sup>

4. On or about August 8, 2025, Pharmacy staff submitted a DEA Form 106 Report of Theft or Loss of Controlled Substances (the "DEA Form 106"). The DEA Form 106 identified the type of theft or loss as "Employee Theft (or Suspected)" and listed the theft or loss as 414 tablets of Clonazepam 2mg.

---

<sup>1</sup> The statements regarding the Respondent's conduct are only intended to provide the Respondent with notice of the basis for the Board's action. They are not intended as, and do not necessarily represent a complete description of the evidence, either documentary or testimonial, to be offered against the Respondent in this matter.

<sup>2</sup> For confidentiality and privacy purposes, the names of individuals and the pharmacy involved in this case are not disclosed in this document. Upon written request, the Administrative Prosecutor will provide the information to the Respondent.

<sup>3</sup> Clonazepam is a Schedule IV controlled substance and is used to treat certain seizure and/or anxiety disorders in adults and children.

5. Pharmacy staff reviewed closed-circuit television that showed the Respondent removing a bottle of Clonazepam 2mg from the pharmacy shelf on August 3, 2025, and placing the bottle in her pocket. The Respondent was seen returning to her workstation where she immediately began texting on her phone.

6. On August 7, 2025, the Respondent was interviewed by Pharmacy staff. During the interview, the Respondent verbally admitted to stealing the Clonazepam 2mg on August 3, 2025. The Respondent indicated during the interview that she agreed to obtain the medication for an acquaintance. The Respondent also indicated that the acquaintance had agreed to pay her three hundred dollars for the medication but did not do so.

#### **CONCLUSIONS OF LAW**

Based on the foregoing Investigative Findings, the Board concludes that the public health, safety, or welfare imperatively requires emergency action in this case, pursuant to Md. Code Ann., State Gov't. § 10-226(c)(2) (2021 Repl. Vol. & 2024 Supp.) and COMAR 10.34.01.12F.

#### **ORDER**

Based on the foregoing Investigative Findings and Conclusions of Law, it is this 20<sup>th</sup> day of October 2025, by a majority of the quorum of the Board, hereby

**ORDERED** that the registration issued to the Respondent to practice as a pharmacy technician in the State of Maryland under registration number: **T31151** is hereby **SUMMARILY SUSPENDED**; and it is further

**ORDERED** that the Respondent is prohibited from practicing as a pharmacy technician in the State of Maryland; and it is further

**ORDERED** that the Respondent has the opportunity to appear before the Board for a post-deprivation show cause hearing for a determination of whether the Summary Suspension should be continued. A request for a post-deprivation show cause hearing must be made in writing to the Board and be made **WITHIN THIRTY (30) CALENDAR DAYS** of the date of this Order; and it is further

**ORDERED** that if the Respondent fails to request a post-deprivation show cause hearing in writing in a timely manner, or if the Respondent requests a post-deprivation show cause hearing but fails to appear before the Board when the hearing is scheduled, the Respondent's registration shall remain **SUSPENDED**; and it is further

**ORDERED** that the Respondent shall immediately return all registrations (wall and wallet sized) to the Board; and it is further

**ORDERED** that this Order for Summary Suspension is a **PUBLIC** document, as defined in Md. Code Ann., General Provision §§ 4-101 *et seq.* & § 4-333 (2019 Rep. Vol. & 2024 Supp.).

10.20.25

Date



Deena Speights-Napata, M.A.  
Executive Director  
Maryland Board of Pharmacy